Analysis on the types of patients with contraindications and non-recommendations for taking Mobosetinib (Anvili)

Mobocertinib (Mobocertinib) is an oral irreversible tyrosine kinase inhibitor (TKI), mainly targeting EGFRExon 20Insertion mutations in patients with non-small cell lung cancer (NSCLC). This type of mutation accounts for about 4% to 12% of EGFR mutations and lacks sensitivity to common first- to third-generation EGFR-TKIs. Therefore, there was a lack of effective targeted treatment options in the past. The emergence of mobosetinib has brought new treatment options to these patients and has received accelerated approval internationally. However, as a new type of targeted drug, its use is contraindicated and the groups not suitable for its use need to be paid special attention to avoid serious adverse events and treatment failure.

1. Core principles of drug taboos

When using mobosetinib, you must strictly follow the contraindications stated in the drug instructions and clinical guidelines. Generally it can be divided into the following aspects:

1.Contraindicated for those who are allergic to drug ingredients

If the patient has a history of severe allergic reaction (including rash, dyspnea, anaphylactic shock, etc.) to mobosetinib or any of its excipients, it is strictly prohibited to use it. Although allergic reactions to targeted drugs are uncommon, when they occur, they are often life-threatening.

2.Patients with severe arrhythmia orQT prolonged interval

Mobosetinib can cause QT interval prolongation, and even lead to serious arrhythmias such as torsade de pointes. It should be prohibited or used with extreme caution in patients with previous significant QT prolongation, concomitant use of other drugs that can prolong QT, or severe electrolyte imbalance.

3.Patients with severe liver function impairment

Mobosetinib is mainly metabolized in the body by the liverCYP3A4 enzyme. If the patient has severe liver function impairment (such as Child-Pugh C grade), the drug clearance rate will decrease, which may lead to excessive blood drug concentration, thereby increasing the risk of toxic and side effects, so it is a prohibited group.

2. Types of people it is not recommended to use

In addition to those with clear contraindications, there are also some patient types for which the use of mobosertinib is not recommended clinically, including:

1.Pregnant and lactating women

Animal experiments suggest that mobosetinib may have adverse effects on fetal development and pose a risk of teratogenesis. There are currently insufficient safety data in human pregnancy and use by pregnant women is not recommended. At the same time, the drug may be secreted through breast milk and potentially toxic to the baby, so breastfeeding women should also avoid using it.

2.Children and adolescent patients

Current clinical trials are mainly focused on adult patients with late-stage NSCLC, and there is no safety and efficacy data in children or adolescents. Therefore, it is not recommended for use in people under the age of 18 unless supported by rigorous clinical trial data.

3.Patients with serious underlying diseases

For example, severe heart failure, uncontrollable hypertension, active severe infection, etc. These diseases may not only aggravate the side effects of moboxetinib, but may also worsen the condition due to drug interactions. Therefore, its use is not recommended or should be used with caution and under strict monitoring in such patients.

4.Patients taking strongCYP3A inhibitors or inducers

Mobosetinib metabolism mainly depends onCYP3A4. If strong CYP3A inhibitors (such as ketoconazole, itraconazole) or inducers (such as rifampicin, carbamazepine) are used at the same time, the plasma concentration of the drug will be significantly affected, resulting in increased toxicity or decreased efficacy. Therefore, moboxetinib is not recommended in patients who cannot discontinue these medications.

3. Common adverse reactions and discontinuation considerations

Common adverse reactions of mobosetinib include diarrhea, rash, nausea, vomiting, fatigue, decreased appetite, anemia, etc. Among them, diarrhea is the most prominent side effect, and some patients even suffer from severe dehydration and electrolyte imbalance. If the patient experiences grade ≥3 adverse reactions (such as severe diarrhea, sustained QT interval prolongation, significant liver function damage), the drug should be discontinued immediately or the dose should be adjusted. For patients who are intolerant to the drug, continued use is not recommended even if there are no clear contraindications.

4. Risk management and suggestions in clinical applications

In order to maximize the efficacy of moboxetinib and reduce risks, the following points should be noted clinically:

1.Pre-treatment screening

All patients should undergo electrocardiogram testing, liver and kidney function evaluation, and electrolyte level testing before taking medication to exclude those with contraindications.

2.Monitoring during treatment

During the course of medication, it is necessary to regularly review the electrocardiogram and monitor changes in the QT interval; also pay attention to liver function, blood routine and electrolyte levels, and adjust the dose in a timely manner if necessary.

3. Pregnancy and contraceptive advice

Women of childbearing age should take reliable contraceptive measures while taking mobosetinib and continue to observe for a period of time after stopping the drug to avoid the risk of pregnancy. Male patients should also be informed of possible effects on sperm fertility.

4.Patient education

Clinicians should strengthen medication education for patients and remind them to pay attention to adverse drug reactions, especially diarrhea, arrhythmia, and skin reactions. Once symptoms worsen, you should seek medical attention immediately instead of stopping or continuing to take the medication without authorization.

Mobosetinib, as an innovative EGFRexon20 insertion mutation-targeting drug, provides a new treatment option for some patients with advanced non-small cell lung cancer. But at the same time, it also has certain contraindications and people who are not recommended to use it. For patients with severe liver function impairment, prolonged QT interval, pregnant women and children, use should be clearly prohibited or avoided; patients with underlying diseases or who are using strong CYP3A modulators should also be carefully considered. In clinical practice, doctors should conduct a comprehensive assessment before using medication and closely monitor during treatment to ensure efficacy and safety to the greatest extent.

Reference link:https://www.drugs.com